{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal allograft",
            "NStudiesAvail": 430108,
            "NStudiesFound": 36,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 36,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Jianming Tan T Jianming, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 2008"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Creatinine and creatinine clearance rate"
                        ],
                        "NCTId": [
                              "NCT00659620"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Tambi Jarmi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of serious adverse events reported. SAEs will include delayed graft function (30 days post-transplant), difficult to control bleeding (intraoperative), sub-scapular kidney hematoma or arteriovenous fistula formation (24 hours postop), and development of stroke, myocardial infarction, or pulmonary embolism (1 year post-transplant)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Serious Adverse Events (SAEs)"
                        ],
                        "NCTId": [
                              "NCT04388761"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Daniel Chambers, MBBS MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Progression-free survival is a composite end-point of freedom from CLAD progression or death from any-cause. CLAD progression is defined as fall in FEV1 > 10% from the baseline (screening visit) FEV1 to the 12 month (week 54) visit."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Progression-free survival"
                        ],
                        "NCTId": [
                              "NCT02709343"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Jianming Tan, M.D and Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence rate of biopsy-proven acute rejection and early renal function recovery"
                        ],
                        "NCTId": [
                              "NCT00658073"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Marlies Reinders, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Primary 1 Safety: rate of (serious) adverse events in the study population 2 Feasibility: determination of the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses"
                        ],
                        "NCTId": [
                              "NCT00734396"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.",
                              "Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The improvement of the fusion of the posterolateral fusion measured on X-rays",
                              "The improvement of the fusion of the posterolateral fusion measured on X-rays and CT scans."
                        ],
                        "NCTId": [
                              "NCT01603836"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Adam Yanke, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "To measure the amount of cytokines and cartilage biomarkers in the synovial fluid of patients undergoing osteochondral allograft transplantation with and without BMAC augmentation at different time points"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Synovial Fluid Cytokine Measurement"
                        ],
                        "NCTId": [
                              "NCT04739930"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Allan D. Kirk, M.D., Ph.D."
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2027"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Operational tolerance (to their kidney transplant) defined by participant remaining off all immunosuppression for 52 weeks after completion of Immunosuppression Withdrawal (ISW) with:\n\nNo evidence of biopsy-proven allograft rejection after initiation of ISW;\nAcceptable renal function, defined as an estimated GFR > 60 ml/min/1.73cm^2 calculated using the CKD-EPI equation or a serum creatinine that has increased no more than 25% above baseline, as assessed at the week 52 visit after completion of ISW;\nNo evidence of sustained transplant renal derived pathologic proteinuria, defined as a persistent protein creatinine ratio of greater than 0.5; and\nNo Donor Specific Antibodies (DSA) at any time after completion of ISW."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Proportion of Participants who Achieve Operational Tolerance"
                        ],
                        "NCTId": [
                              "NCT03504241"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 1, 2011"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary outcome evaluated was the avoiding or delaying of total hip replacement (THR)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Avoiding arthroplasty"
                        ],
                        "NCTId": [
                              "NCT04210440"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Fu-Sheng Wang, PHD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Incidence rate of acute rejection and early liver function recovery"
                        ],
                        "NCTId": [
                              "NCT01690247"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Maurice HV Strickland, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "No occurrence of adverse events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Adverse Events"
                        ],
                        "NCTId": [
                              "NCT02235844"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Timucin Taner, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of subjects to have biopsy-proven worsening kidney allograft rejection",
                              "Number of Grade 3 or higher AEs attributable to the A-MSC infusion including infusion reaction/cytokine release syndrome, per the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). Cytokine Release Syndrome (CRS) will be defined using the American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cell"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Worsening kidney allograft rejection",
                              "Adverse Events"
                        ],
                        "NCTId": [
                              "NCT05456243"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Enrolling by invitation"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 3, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Signal intensity of the ACL graft on T2 weighted MRI imaging compared to a reference structures' signal intensity"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Signal to Noise Quotient"
                        ],
                        "NCTId": [
                              "NCT04650568"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Per-Ola Carlsson, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 1, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "measured through the registration of adverse events and other safety parameters such as hypoglycemia, allergic reactions, ophthalmologic examination, ECG, vital signs and laboratory assessments.",
                              "Delta-change of C-peptide Area Under the Curve (AUC) (0-120 min) for Mixed Meal Tolerance Test (MMTT) at day 372 following WJMSC/Placebo infusion when compared to test performed before start of treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety; measured through set safety parameters",
                              "Efficacy; comparison of the intervention versus placebo at day 372 versus start of treatment"
                        ],
                        "NCTId": [
                              "NCT03406585"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "20 patients who meet the criteria for Expanded Access as determined by the principal investigator and who do not otherwise qualify for an available clinical trial"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse/serious adverse events"
                        ],
                        "NCTId": [
                              "NCT05215288"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Dany Anglicheau, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 19, 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Renal allograft fibrosis at one year posttransplantation"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Renal allograft fibrosis"
                        ],
                        "NCTId": [
                              "NCT01380847"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Arash Khojasteh, DMD, OMFS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "the amount of regenerated bone will be assessed by Image Pro software in CBCT images",
                              "the percent of regenerated bone will be assessed on bone biopsies obtained during implant insertion by H&E staining by microscope"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "amount of regenerated bone",
                              "amount of regenerated bone"
                        ],
                        "NCTId": [
                              "NCT02745379"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Ekkehard Sturm, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "In order to evaluate and quantifiy acute clinical complications related to MSC infusion, the investigators defined the MYSTEP score, a specific pediatric infusional toxicity scoring system (adapted from MiSOT-I score). The score focusses on description of intraportal, pulmonary and systemic toxicity. For each of these three modalities, degrees of severity between 0 (no treatment emergent adverse event) and 3 (severe treatment emergent adverse event) have been defined.",
                              "A particular focus will be on viral infections and reactivation (ADV, HCMV, EBV, Hepatitis B, Hepatitis C and Hepatitis E), bacterial or fungal infections.",
                              "Graft function after liver transplantation, measured by aminotransferase and gamma glutamyl transferase activity, bilirubin, albumin and INR."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with MYSTEP-score grade 3 and grade 2 (toxicity of MSC infusion)",
                              "Number of participants with occurrence of any severe adverse events (SAE)",
                              "Graft function after liver transplantation - Number of participants with abnormal liver tests"
                        ],
                        "NCTId": [
                              "NCT02957552"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "Jianming Tan, professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Exogenous insulin requirement",
                              "Hemoglobin A1c",
                              "Glucose and C-peptide levels"
                        ],
                        "NCTId": [
                              "NCT00646724"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Marlies EJ Reinders, MD/PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Fibrosis by quantitative Sirius Red scoring of MSC treated and untreated groups"
                        ],
                        "NCTId": [
                              "NCT02057965"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [
                              "Arash Khojasteh, DMD, OMFS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "the amount of regenerated bone will be assessed by Image Pro software in CBCT images",
                              "the percent of regenerated bone will be assessed on bone biopsies obtained during implant insertion by H&E staining by microscope"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "amount of regenerated bone",
                              "amount of regenerated bone"
                        ],
                        "NCTId": [
                              "NCT02745366"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Raymond J Linovitz, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Fusion Success"
                        ],
                        "NCTId": [
                              "NCT00988338"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Tan Jianming, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Changes of the immunosuppressant by reducing 30% of CNI dosage."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Effects of autologous SVF derived MSC transplantation on reducing the dosage of CNI by 30% in Kidney Transplantation from Chinese Donation after Citizen Death"
                        ],
                        "NCTId": [
                              "NCT02492490"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [
                              "T Srinivas, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [
                              "FLECHNS@ccf.org"
                        ],
                        "PointOfContactOrganization": [
                              "Cleveland Clinic"
                        ],
                        "PointOfContactPhone": [
                              "216 445-5772"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Dr. Stuart Flechner"
                        ],
                        "PrimaryCompletionDate": [
                              "December 2014"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary analyses will compare biopsy-derived measures of fibrosis in the Tac-maintenance and SRL groups using the t-test."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Biopsy-derived Measures of Fibrosis"
                        ],
                        "NCTId": [
                              "NCT01166724"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [
                              "Bojana Maksimovi\u0107, MD",
                              "Mladen Knotek, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 4"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Difference in 6-month changes in chronic Banff scores between spironolactone and retrospective control group"
                        ],
                        "NCTId": [
                              "NCT01510795"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 26, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will perform as many sit-to-stand movements as they can in 30 seconds and then will rate pain",
                              "Participants will perform a supine to upright movement as quickly as they can and then will rate pain",
                              "Participants will ascend and decent 10 stairs as quickly as they can and then will rate pain"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months",
                              "Change in pain during sit-to-stand over 3 months",
                              "Change in pain during supine to upright over 3 months",
                              "Change in pain during ascent/decent stairs over 3 months"
                        ],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Changxi Wang, M.D., Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "eGFR at one month post-transplant"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Estimated glomerular filtration rate"
                        ],
                        "NCTId": [
                              "NCT02561767"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Ahmed O Gaber, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Infusional toxicity will be assessed as the occurrence of either 1) two or more participants having deep vein thrombosis (Grade 2 thrombotic event); 2) any participant having evidence of the first-pass phenomenon of cells trapping in the lung as evidenced by (a) shortness of breath at rest, (b) requiring ventilator support, or (c) pulmonary edema with hypoxia requiring support; or 3) Grade 4 hypertension or hypotension; or 4) acute myocardial infarction; or 5) new onset congestive heart failure; or 6) capillary leak syndrome; or 7) acute kidney injury; or 8) biopsy-proven rejection."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants without any infusional toxicity, occurring within 24 hours of infusion."
                        ],
                        "NCTId": [
                              "NCT03478215"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT01301664"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2013"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "all patients will be transplanted bone marrow derived mesenchymal stem cells belonging to the opposite sex in order to genetically determine the mature hepatocyte"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "differantiation of transplanted mesenchymal stem cells to hepatocytes in post treatment liver biopsies"
                        ],
                        "NCTId": [
                              "NCT01378182"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [
                              "Changxi Wang, M.D., Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "eGFR at one month post transplant"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Estimated glomerular filtration rate"
                        ],
                        "NCTId": [
                              "NCT02563366"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [
                              "Changxi Wang, M.D., Ph.D"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "eGFR at month 12 after enrollment"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Estimated glomerular filtration rate (eGFR)"
                        ],
                        "NCTId": [
                              "NCT02563340"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Clinical horizontal bone augmentation results through direct measurement."
                        ],
                        "NCTId": [
                              "NCT02396056"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [
                              "Farhan N Siddiqi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "Yes"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Numeric Pain Rating Scale (NPRS)",
                              "Oswestry Disability Index (ODI)"
                        ],
                        "NCTId": [
                              "NCT02529566"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Suspended"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint will be the safety and tolerability of IV administration of allogeneic mesenchymal bone marrow cells (aMBMC) during the twelve month study period as determined by the incidence and severity of adverse events, clinically significant changes on clinical laboratory tests, vital signs, physical and cutaneous examinations, 12 lead ECGs and CT scans of the chest (without contrast)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "MSC Safety and Tolerability"
                        ],
                        "NCTId": [
                              "NCT01771679"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [
                              "Hong Hoe Koo, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2010"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "- Day of neutrophil engraftment - Day of platelet engraftment - Evaluation of chimerism - Evaluation of engraftment rate"
                        ],
                        "NCTId": [
                              "NCT00823316"
                        ]
                  }
            ]
      }
}